jRCT2080224127已完成1 期
A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Phase 1, Open-label, Non-controlled, Multi-center, Repeat dose, Dose escalation study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Subjects must have an advanced, relapsed or refractory cancer
- •For a cohort of hematological cancers,subjects must have an MDS, CMML or AML (excluding APL) according to World Health Organization (WHO) criteria.
- •As for MDS, subjects must be considered an intermediate, high, or very high risk according to the Revised International Prognostic Scoring System (IPSS-R)
- •Subjects must relapse or refractory to standard therapies, or not eligible for standard therapies.
- •Subjects must be an eastern cooperative oncology group (ECOG) performance status of 0 or 1
- •Subjects must have more than 90 days life expectancy
- •Subjects must have adequate major organ functions
排除标准
- •Patients with uncontrolled complications
- •Patients with active multiple primary cancers that require specific treatments
- •In a cohort of hematologic cancer patients, those who have received allogenic hematopoietic stem cell transplantation
- •Patients having a medical history of congenital retinal degenerative disease,optic nerve or retinal diseases
结局指标
主要结局
-
safety efficacy Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer PatientsAdvanced,relapsed or refractory cancersJPRN-jRCT2080224127Chordia Therapeutics Inc.79
进行中（未招募）
1 期
Effect of CT1812 Treatment on Aß Oligomer Displacement into CSFSponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2018-000163-89-SECognition Therapeutics, Inc.18
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-BETaiho Oncology, Inc.128
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-ESAstex Pharmaceuticals, Inc.168
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-DETaiho Oncology, Inc.168